Patent intelligence · US
US 9872918
Hydroxyl-polymer-drug-protein conjugates
Hydroxyl-polymer-drug-protein conjugates
Patent details — US 9872918
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 23, 2018
- Expiration
- Jan 18, 2038
- Applicant
- Mersana Therapeutics, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/4412, A61K31/475, A61K31/5377
Quick answer
US 9872918 (Hydroxyl-polymer-drug-protein conjugates) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Jan 23, 2018. Expires Jan 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mersana Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/4412, A61K31/475, A61K31/5377, A61K38/05, A61K38/08
More from Mersana Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 9872918?
US 9872918 (Hydroxyl-polymer-drug-protein conjugates) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Jan 23, 2018. Expires Jan 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9872918?
Mersana Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 9872918 expire?
Our index shows an expiration date of Jan 18, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.